Scholars Central

Conference abstractPublished 22 May 2017

Procedural safety and one month outcome of patients treated with magnesium bioresorbable scaffold

Authors: Nicholas Chua

University of Technology MARA (UiTM), Malaysia

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Magnesium Bioresorbable Scaffold (BRS) was launched last year. The advantage of using BRS include, reduced long-term complications such as stent fracture, late stent thrombosis and in-stent restenosis with return of normal vasomotor function and late lumen gain with plaque regression. However, procedural safety and long-term outcome data is scarce. Objective: The objective of the study is to identify safety and outcome of patients undergoing Percutaneous Coronary Intervention (PCI) with magnesium BRS. Materials & Methods: This was a prospective, observational single center study conducted in UiTM Sungai Buloh from 1st November 2016 to 14th February 2017. Results: 7 patients who were enrolled had mean age of 46 (±9). All were male. Ethnicity breakdown showed 5 Malays, 1 Chinese and 1 Indian. Cardiovascular risk assessment revealed 85.7% diabetes mellitus, 42.9% smokers, 28.6% hypertension and 28.6% dyslipidemia. Target vessels treated were 6 left anterior descending (LAD) and 1 right coronary artery (RCA). Out of the 7 patients, 28.6% were type A lesions, 42.8% were type B1 and 28.5% were type C. Among those, 4 involved LAD-D1 bifurcations and 2 were Chronic Total Occlusions (CTO). The lesions were prepared with semi-compliant balloons in 5 cases and non-compliant balloons in 2 cases. The balloon-to-stent ratio were 1:1 (n=1), 0.92:1 (n=1), 0.85:1 (n=4) and 0.83:1 (n=1). The magnesium BRS diameters used were 3.5 mm (n=4) and 3.0 mm (n=3) with length of 15 mm (n=1), 20 mm (n=4) and 25 mm (n=2). Post-dilatation in one patient was carried out with non-compliant balloon of equal diameter to the stent, while the rest had upsizing with +0.5 mm larger balloons. Procedural outcome was 100% successful. At one-month follow-up, there were no symptoms, MACE or TLR. Conclusions: We demonstrated safety and good short-term outcome in the use of magnesium BRS in our cohort. However, larger cohort and long-term outcome monitoring would better delineate the safety and efficacy of this BRS.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • BylineArticles whose byline prints “Nicholas Chua”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels